Physician profile
Lawrence E Gelber
NPI 1003865726
$1,877,321.17
in general payments reported to CMS, 2019-2025
37 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 76% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389K · 2020: $8,850 · 2021: $1.4M · 2022: $45K · 2023: $2,698 · 2024: $3,201 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,273 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,272.57 |
| Education | $240.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $1,863,829.69 | 2019-2024 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $2,246.18 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,506.31 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,409.92 | 2019-2025 | |
| Genentech USA, INC. | $1,127.42 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $874.21 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $779.06 | 2021-2025 | Tezspire |
| Optinose US, INC. | $709.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $690.42 | 2020-2025 | |
| Csl Behring | $678.61 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $483.87 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $313.31 | 2021-2025 | Orladeyo |
| Pfizer INC. | $289.86 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.65 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Teva Pharmaceuticals USA, INC. | $263.65 | 2019-2023 | Airduo Digihaler |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,193,535.36 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gelber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.